Daniel Chao

Daniel Chao


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2020 in ACS Nano
Verified
Journal Article
Closed access
GLGeorge J Lu
George J Lu
LCLi-Dek Chou
Li-Dek Chou
DMDina Malounda
Dina Malounda
APAmit K. Patel
Amit K. Patel
DWDerek S. Welsbie
Derek S. Welsbie
MSMikhail G. Shapiro
Mikhail G. Shapiro

1 August 2019 in Ophthalmology Retina
Verified
Journal Article
Closed access
RCRahul Chaturvedi
Rahul Chaturvedi
KWKendall W. Wannamaker
Kendall W. Wannamaker
PRPaul Riviere
Paul Riviere
AKArshad M. Khanani
Arshad M. Khanani
CWCharles C. Wykoff
Charles C. Wykoff
DCDaniel Chao
Daniel Chao

4 September 2018 in Translational Vision Science & Technology
Verified
Journal Article
Open access
PDF file
BNBrian J. Nguyen
Brian J. Nguyen
YKYeji Kim
Yeji Kim
KPKathryn Park
Kathryn Park
ACAllison J. Chen
Allison J. Chen
SCScarlett Chen
Scarlett Chen
DCDaniel Chao
Daniel Chao
Purpose: We evaluate patient-reported quality of life outcomes in severely visually impaired (SVI) individuals using the Aira system, an on demand assistive wearable technology. Methods: Aira is an on-demand assistive wearable technology designed for the severely visually impaired (visual acuity of better eye <20/200). The user wears glasses with a video camera mounted that, when activated, livestreams to a human agent who assists the user in the specified task. Aira subscribers were recruited consecutively and administered the 28-item Impact of Vision Impairment-Very Low Vision (IVI-VLV) Questionnaire, a previously validated survey for vision-related quality of life specifically for low vision individuals. The questionnaire was administered by phone before starting Aira and at 3-month follow-up. Total score as well as validated subset scores of activities of daily living, mobility and safety (ADLMS) and emotional wellbeing (EWB) were assessed. Results: A total of 69 participants (mean age, 52.1; 35 female, 34 male) were recruited with a mean of 108 (SD = 19.7) days to follow-up. Mean total minutes used over the interval were 334.1 (SD = 318.5). Initial total score (mean 51.7 ± 18.6) significantly improved at follow-up (mean 62.2 ± 15.0; P < 0.0001) with mean change +10.4 ± 12.5. ADLMS subset score (mean 30.4 ± 10.8) significantly improved at follow-up (mean 36.6 ± 8.8; P < 0.0001) with mean change +6.5 ± 8.7. EWB subset score (mean 21.6 ± 8.8) significantly improved at follow-up (mean 25.6 ± 7.9 respectively; P < 0.0001) with mean change +4.0 ± 5.2. There was no correlation between minutes used and improvement in total (r = −0.205, P = 0.098), ADLMS (r = −0.237, P = 0.055), and EWB (r = −0.242, P = 0.051) scores. Conclusions: In this exploratory study, regardless of minutes used, the use of Aira significantly improves IVI-VLV total score and ADLMS and EWB subscores for SVI individuals. This improvement is not correlated with total minutes used. Translational Relevance: The Aira assistive technology system may provide improvement in quality of life for low vision patients and is worthy of further study to assess the use of this technology to assist SVI patients.

1 September 2019 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
BNBrian J Nguyen
Brian J Nguyen
WCWilliam S Chen
William S Chen
ACAllison J Chen
Allison J Chen
AUAndrew Utt
Andrew Utt
EHEmily Hill
Emily Hill
DCDaniel Chao
Daniel Chao
Purpose: To systematically evaluate the needs of low vision individuals through call data obtained through the Aira assistive technology system. Patients and methods: Aira (Aira Tech Corporation, La Jolla, CA, USA) is an on-demand assistive wearable technology designed for individuals with low vision. The user wears glasses with an integrated front-facing video camera that connects with a remote human agent who assists the user with the specified task. Call types, temporal characteristics, and duration of call were compared by gender and vision status (low vision, light perception, and blind). Chi-square tests, t-tests, ANOVA, linear regression and Poisson regression analyses were performed. Results: 878 subscribers placed 10,022 total calls (4759 female, 5263 male) over 3 months. The most common categories were reading (35%), navigation (33%), and home management (16%). The distribution of categories (χ2=49.3, p<0.001), duration (t=−7.59, p<0.0001) and time of call (χ2=37.4, p<0.001) differed by gender. The distribution of categories (χ2=61, p<0.001), duration (F=13.7, p<0.0001), and time of call (χ2=36.9, p<0.001) differed by vision status. Blind [adjusted IRR=1.68 (95% CI: 1.56–1.79)] and light perception users [adjusted IRR=1.43 (95% CI: 1.32–1.53)] had increased usage compared to low vision users. Women had higher usage than men [adjusted IRR=1.09 (95% CI: 1.04–1.13)]. Conclusion: To our knowledge, this is the first large-scale needs assessment of 878 low vision individuals over 10,022 calls. The most common categories were reading, navigation, and home management. Distribution of call types, duration, and time of call differed significantly by gender and vision status. Blind and light perception users had higher usage rates than those with low vision. Women had higher usage rates than men. This large-scale needs analysis of low vision individuals provides insight into utilization patterns across varying levels of vision loss and gender, which will guide future evolutions of assistive technology by tailoring future hardware and software upgrades.

9 April 2020 in JCI Insight
Verified
Journal Article
Closed access
PDF file
ELEun-Jin Lee
Eun-Jin Lee
WCWei-Chieh Jerry Chiang
Wei-Chieh Jerry Chiang
HKHeike Kroeger
Heike Kroeger
CBChloe Xiaoke Bi
Chloe Xiaoke Bi
DCDaniel Chao
Daniel Chao
JLJonathan Lin
Jonathan Lin
Achromatopsia (ACHM) is an autosomal recessive disease that results in severe visual loss. Symptoms of ACHM include impaired visual acuity, nystagmus, and photoaversion starting from infancy; furthermore, ACHM is associated with bilateral foveal hypoplasia and absent or severely reduced cone photoreceptor function on electroretinography. Here, we performed genetic sequencing in 3 patients from 2 families with ACHM, identifying and functionally characterizing 2 mutations in the activating transcription factor 6 ( ATF6 ) gene. We identified a homozygous deletion covering exons 8–14 of the ATF6 gene from 2 siblings from the same family. In another patient from a different family, we identified a heterozygous deletion covering exons 2 and 3 of the ATF6 gene found in trans with a previously identified ATF6 c.970C>T (p.Arg324Cys) ACHM disease allele. Recombinant ATF6 proteins bearing these exon deletions showed markedly impaired transcriptional activity by qPCR and RNA-Seq analysis compared with WT-ATF6. Finally, RNAscope revealed that ATF6 and the related ATF6B transcripts were expressed in cones as well as in all retinal layers in normal human retina. Overall, our data identify loss-of-function ATF6 disease alleles that cause human foveal disease.

9 March 2020 in Translational Vision Science & Technology
Verified
Journal Article
Open access
PDF file
KPKathryn Park
Kathryn Park
YKYeji Kim
Yeji Kim
BNBrian J. Nguyen
Brian J. Nguyen
ACAllison Chen
Allison Chen
DCDaniel Chao
Daniel Chao
Purpose: To assess patient-reported quality of life outcome improvements in severely visually impaired (SVI) individuals using the Aira system over a 1-year follow-up period. Methods: Aira is an on-demand assistive technology designed for SVI. Aira subscribers were recruited and administered the validated 28-item Impact of Vision Impairment-Very Low Vision Questionnaire by phone before starting Aira with follow-ups at 3 months and 1 year. Total score and validated subset scores of activities of daily living, mobility, and safety (ADLMS) and emotional well-being (EWB) were assessed. Pearson correlation analyses and paired t-tests were used to examine the data. Results: Fifty participants (mean, age, 52.5 years; 25 males, 25 females) were recruited with a mean of 401 ± 66.3 days to follow-up. The initial total score (mean, 53.1 ± 18.9) significantly improved at 1 year (mean, 63.1 ± 16.2; P = 0.0002). The initial ADLMS score (mean, 30.7 ± 11.3) significantly improved at 1 year (mean, 37.2 ± 10.7; P = 0.001). The initial EWB score (mean, 22.5 ± 8.5) significantly improved at 1 year (mean, 25.9 ± 8.0; P = 0.0001). There was no significant difference between the 3-month and 1-year total (P = 0.972), ADLMS (P = 0.897), and EWB scores (P = 0.700). There was a significant correlation between minutes used and improvement in total (r = 0.371; P = 0.009), ADLMS (r = 0.302; P = 0.035), and EWB (r = 0.439; P = 0.002) scores. Conclusions: Aira use significantly improves Impact of Vision Impairment-Very Low Vision total, ADLMS, and EWB scores for SVI individuals at 3 months. This improvement is sustained at the 1-year follow-up and correlated with total minutes used. Translational Relevance: Aira technology may provide sustained improvement in quality of life for SVI, and further study to evaluate the usefulness of this technology to assist SVI may be beneficial.